
Loading, please wait...

Loading, please wait...

Axillary lymph node dissection is a critical procedure for many breast cancer patients undergoing surgical treatment. However, this surgical intervention carries a significant lifetime risk of developing lymphedema. This condition, known as breast cancer-related lymphedema (BCRL), affects approximately 20-30% of patients. During a mastectomy, surgeons may perform the dissection through the primary mastectomy incision or a separate axillary incision. Historically, clinicians have debated whether a separate incision causes more lymphatic disruption, potentially increasing lymphedema rates.
A recent retrospective study by Wang J et al. analyzed 1,036 patients to determine if the incision site impacts BCRL outcomes. The researchers compared 483 patients who received a separate axillary incision to 553 patients who underwent dissection through the mastectomy incision. The results indicated that separate axillary incisions do not increase lymphedema rates. Specifically, the lymphedema rate was 29% for the separate incision group versus 30% for the mastectomy incision group. Moreover, the difference between these cohorts was not statistically significant, with a p-value of 0.77.
Multivariable logistical regression further supported these clinical findings. Specifically, the analysis showed that patients undergoing axillary lymph node dissection via a separate incision did not have significantly greater odds of developing swelling (OR 0.89). Consequently, surgeons can choose the incision site based on oncologic safety and technical accessibility rather than fear of lymphedema. Furthermore, the median time to lymphedema development was 15 months, suggesting that long-term monitoring is essential regardless of the incision type used. In addition, prioritizing the thoroughness of lymph node retrieval remains the most important factor for oncologic success.
No, research indicates that performing the dissection through a separate incision does not significantly increase the risk of lymphedema compared to using the mastectomy incision.
While the incision type is not a major factor, significant risk factors include a high body mass index (BMI), regional lymph node radiation, and the total number of lymph nodes removed during the procedure.
The median time to development is approximately 15 months, though it can occur at any time during a patient\'s life following axillary lymph node dissection.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.
References
1. Wang J et al. Axillary Lymph Node Dissection Through a Separate Incision Does Not Increase Rates of Breast Cancer-Related Lymphedema. Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-026-19215-x. PMID: 41665789.
2. Lindqvist EK, et al. Risk factors for lymphedema after breast cancer treatment. Lymphatic Research and Biology. 2022.
3. National Cancer Institute. Lymphedema (PDQ®)–Health Professional Version. 2024.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A study of 1,036 patients found that performing axillary lymph node dissection through a separate incision does not increase lymphedema risk....
7 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today